BioSpace News Archive

GlycoMimetics, Inc. (Nasdaq: GLYC) a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers and inflammatory diseases, today reported its financial results and highlights for the quarter and year ended December 31, 2022.

Novocure (NASDAQ: NVCR) today announced that Kristin Stafford has been elected to Novocure’s Board of Directors.

Wave Life Sciences Ltd. announced today that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Guggenheim Genomic Medicines and Rare Disease Days in New York City on Monday, April 3, 2023 at 2:10 p.m. ET.

Third Harmonic Bio, Inc. today announced financial results for the fourth quarter and full year ended December 31, 2022.

Axial Therapeutics today announced key promotions in its research and development organization.

Akari Therapeutics, Plc announced regulatory authorities in Poland and the U.K. have approved amendments to the company’s Investigational Medicinal Product Dossier and Clinical Trial Authorisation, respectively, for clinical use of the third-generation drug substance manufacturing process that increases the final yield of nomacopan by at least 5-fold.

ICON plc announced that it will release its financial results for the first quarter 2023 after the market closes on Wednesday, April 26, 2023.

Axonics, Inc., a global medical technology company that is developing and commercializing novel products for the treatment of bladder and bowel dysfunction, announced it ranked No. 2 on the Financial Times 2023 list of the fastest growing companies in the Americas.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the European Commission (EC) approved Libtayo ® in combination with platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with ≥1% PD-L1 expression.

EpicentRx, Inc. (“EpicentRx”), announced today that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation to RRx-001, a direct NLRP3 inhibitor and Nrf2.